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Hitoshi Yamazaki1*, Teppei Ohyama2, Toshiki Tsuboi2, Yoshinori Taoka2, Dai Kohguchi2, Hiroyoshi Iguchi3
and Teruaki Ao2Abstract: Prostatic stromal sarcoma is a fairly rare tumor that constitutes approximately 0.1–0.2% of all prostatic
cancers. Detailed characteristics of the tumor are still unclear due to its rarity.
We describe a case of prostatic stromal sarcoma in a 63 year-old man who suffered from urinary obstructive
symptoms. Palliative transuterine resection was performed and the preliminary histopathological diagnosis was
neuroendocrine carcinoma. After chemotherapy, total pelvic exenteration was performed. Histopathologically, the
tumor was composed of monotonously proliferating small to medium-sized round cells, which existed in compact
islands with loose or dense fibrovascular networks. Immunohistochemically, the tumor cells were widely positive for
vimentin, CD56, CD99 and focally positive for synaptophysin, CD10, progesterone receptor, desmin and CD34, but
negative for EMA, cytokeratin, estrogen receptor, S-100 and myoglobin. Most of the previously reported tumors
exhibited positive stainability for CD10 and progesterone receptor. In addition to these markers, expressions of
CD56, CD99 and synaptophysin were characteristically detected in our case. To the best of our knowledge, we
present the first case of prostatic stromal sarcoma with characteristic immunohistochemical staining properties.
Although the biological characteristics of this rare tumor have not yet been elucidated, these findings suggest
prostatic stromal sarcoma can potentially show neuroectodermal differentiation.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7291874028051262
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Neuroectodermal differentiationBackground
Prostatic stromal sarcoma (PSS) is a fairly rare tumor,
constituting approximately 0.1% of all prostatic cancers
[1,2]. Prostatic sarcoma and related proliferative lesions,
including prostatic phyllodes tumors, have been classi-
fied as prostatic stromal tumors of uncertain malignant
potential (STUMP) and prostatic stromal sarcoma (PSS)
based on cellularity, mitotic index, cellular atypia and
necrosis (WHO 2004) [3]. Some STUMP cases were
reported as malignant transformation into PSS [4].
There has not yet been a clear differentiation between
PSS and STUMP due to the rarity of these tumors. In
this article, prostatic stromal sarcoma has potentially
neuroectodermal characteristics.* Correspondence: powder1104@hotmail.com
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The patient was a 63 year-old man who presented to the
urologist with a one week history of dysuria, pollakiuria
and an unrelieved feeling after urination. He had a previ-
ous history of diabetes mellitus and asymptomatic mul-
tiple brain infarction. He habitually drank alcohol and
smoked and his mother died of gastric cancer. Abdom-
inal ultrasonography revealed 343 ml of residual urine
volume. Computed tomography revealed a prostatic
mass lesion which protruded into the bladder space
(Figure 1a). Gadrinium-enhanced T1 weighted magnetic
resonance imaging also revealed the prostatic mass le-
sion had irregularly high signals (Figure 1b). Based on
our clinical diagnosis of benign prostatic hypertrophy,
palliative transurethral resection was performed. The
specimen consisted of 20 grams of piecemealed prostate
that was totally embedded in paraffin and histologically
analyzed. Sections showed monotonously proliferatingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Image analysis. a) Computed tomography shows a prostatic non-homogenous mass lesion irregularly protrudingd into the bladder
space. b) Gadrinium-enhanced T1 weighted magnetic resonance imaging shows a heterogeneous hyperintense mass.
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tous stroma with coarseness and fineness and sparse or
dense patterns. The residual prostatic glands were iden-
tified. Immunohistochemically, the tumor cells were
positive for vimentin, CD56, synaptophysin (focal) but
negative for EMA, cytokeratin, S-100. The preliminary
histopathological diagnosis to decide the strategy for fur-
ther therapy was neuroendocrine carcinoma. He took
one series of chemotherapy, a combination of cisplatin
and irinotecan. Ten days after the last day of the chemo-
therapy, suprapubital radical cystprostatectomy with
rethrotectomy was performed. During the operation, the
urinary bladder could be detached from the rectum with
difficulty. Finally, low anterior rectal resection was add-
itionally performed, resulting in total pelvic exenteration.
When the urethra was cut, a part of the tumor was
pressed down from the urethral cavity. The gross fea-
tures of the tumor were elastic soft and translucently
whitish in color. After fixation in 10% formaldehyde the
prostate weighed 125 g and contained an ill-defined gray
whitish mass lesion, which focally exhibited necrosis
(Figure 2). The bladder and the retroperitoneal cavityFigure 2 Cut surface of the tumor. The prostate and the bladder
space are widely occupied by the tumor tissue, which exhibited a
whitish-yellow multinodular appearance with focal necrosis.were diffusely infiltrated by the whitish tumor, which
was directly connected to the prostatic tumor. Although
the rectum was attached to the tumor mass, the rectal
parenchyma was free from tumor invasion. The bladder
space was occupied by the tumor and narrowed, result-
ing in a slit-like space. Serial sections were analyzed and
revealed a round cell sarcomatous tumor with occasional
higher cellularity than that in the previous transuterine
resection. Tumor necrosis was occasionally identified.
The N/C ratio of the tumor cells was a relatively high
grade. Mitotic activity was measured as 12/10 HPF in
the higher cellularity area. The residual prostatic glands
were compressed to the periphery (Figure 3a). No lymph
nodal metastasis was observed. Immunohistochemically,
the tumor cells were widely positive for vimentin, CD56,
CD99 and focally positive for synaptophysin, CD10, pro-
gesterone receptor, desmin and CD34, but negative for
EMA, cytokeratin, estrogen receptor, S-100, GFAP and
myoglobin (Figure 3b,c,d). The Ki-67 index was about
70%. We finally diagnosed the tumor as prostatic stro-
mal sarcoma. Sixteen months later, the patient is alive
without local recurrence or distant metastasis.
Discussion
Prostatic stromal sarcoma is a rare tumor that constitu-
tes approximately 0.1–0.2% of all prostatic cancers [1,2].
Prostatic mesenchymal tumors sometimes cannot be
clearly classified as histological entities due to their rar-
ity [5]. Except for prostatic mesenchymal tumors with
specialized differentiation, a histologically characteristic
classification involves prostatic stromal sarcoma and
prostatic stromal proliferation of uncertain malignant
potential (STUMP) [6-8]. These tumors have been
described on the basis of the histological similarity to
phyllodes tumors and have to be differentially diagnosed
as other specialized types of tumor, such as GIST, leio-
myosarcoma, rhabdomyosarcoma(RMS), and fibrosar-
coma [3]. RMS is the most common sarcoma of the
prostate, but is rarely reported in adult patients [9].
Figure 3 Microscopic findings. a)The tumor was made up of sarcomatoid oval to spindle cells. (HE x 100) b) Immunostaining with CD56
showed positive results for tumor cells on the cell membrane (CD56 x 200). c) Immunostaining with synaptophysin focally showed positive
results for the tumor cells in the cytoplasm (synaptophysin x 200). d) Immunostaining with CD99 showed positive results for tumor cells on the
cell membrane (CD99 x 200).
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hormone receptors, especially progesterone receptor.
These tumors seem to be derived from female hormone-
dependent stromal cells [10]. Depending on the cellularity,
mitosis and necrosis, these two tumors are histologically
evaluated. An acceptable histological grading of stromal
sarcoma has not yet been proposed due to the rarity of
the tumor. Hasegawa reported that the ki-67 index was
related to the prognosis of the tumor [4].
Recent immunohistochemical analysis revealed that
both prostatic stromal sarcoma and STUMP usually ex-
press CD10, CD34 and the progesterone receptor
[3,7,8,10-12]. This tumor sometimes positively reacts
with smooth muscle actin. However, the detailed histo-
pathological characteristics of the tumor cells have not
yet been clearly elucidated. Kim reported a case of pros-
tatic stromal sarcoma with rhabdoid features [13]. The
tumor in our case was positive for CD56, CD99 (to our
knowledge the second reported case) [14], synaptophysin
and negative for EMA and cytokeratin. This is the first
description of prostatic stromal sarcoma with immuno-
histochemically positive stainability for synaptophysin.
There are other prostatic non-epithelial malignancies with
potential neuroectodermal differentiation such as carcino-
sarcoma, ectomesenchymoma and primitive neuroecto-
dermal tumor (PNET), which have to be distinguishedfrom our case of prostatic stromal sarcoma. Patient age is
a useful marker for differential diagnosis, although PNET
and malignant ectomesenchymoma are rarely reported in
young adult prostate cancer patients [15-18]. Most PNET
cases reveal positive immunoreactivity for CD99, but are
negative for progesterone receptor. Carcinosarcoma con-
tains elements of epithelial malignancy which exhibit
some types of cytokeratins.
PSS is suspiciously derived from mesenchymal pluri-
potent stem cells in the prostatic stroma. As few cases of
STUMP change to PSS in the history, some genetic
transformations are considered to be related to PSS
[4,19]. Arva showed that some cases of prostatic squa-
mous cell carcinoma were derived from hormonal or
radiation-treated prostatic adenocarcinoma [20]. Unex-
pected irradiation may be one of the risk factors of PSS
[21,22]. Babarović reported a case of high grade angio-
sarcoma arising in fibroadenoma and suggested the pos-
sibility that severe inflammatory reaction, for example
silicon granuloma, may cause malignant transformation
of stromal cells in the affected area [23,24]. These factors
may give rise to an exuberant stromal response and
cause some genetic events in the mesenchymal pluripo-
tent stem cells. We could classify PSS as two categories,
which are de novo tumorigenesis and malignant trans-
formation step by step [20]. However, there are no
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mal tumorigenesis. Fibroblast growth factor 8 (FGF8),
the eighth member of the fibroblast growth factor family
contains alternatively spliced mRNA isoforms. Fibroblast
growth factor 8b(FGF8b) is an androgen-induced growth
factor with potent oncogenic activity [25-27]. Elo
reported the results of prostate-targeted fibroblast
growth factor 8b transgenic mice [28]. These mice
showed progressive changes in prostatic stroma, as well
as the prostatic epithelium. Furthermore, FGF8b is the
predominant FGF8 spliceform necessary for proper pos-
terior neural formation in Xenopus [29]. Amsterdam
reported the relationship between fgf8 misregulation and
neuronal tumors in Zebrafish [30]. This knowledge
suggests FBF8b is related to potential neuroectodermal
differentiation in prostatic stromal tumorigenesis. Some
hormonal imbalances, including androgen imbalance,
may cause prostatic stromal progression, which could
lead to prostatic stromal neoplasia. We hereby point
out that PSS may also possess neuroectodermal
characteristics.
Conclusions
We describe a rare case of prostatic stromal sarcoma
(PSS) presenting with characteristic immunohistochem-
ical staining properties. To our knowledge, this case is
the first case of PSS with positive stainability for synap-
tophysin, as well as CD99 and CD56.
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